drugset / Trial / NCT05106777
Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose is to evaluate the effectiveness and safety of Surufatinib in patients with osteosarcoma and soft tissue sarcoma after Standard chemotherapy therapy.
Timeline
- Start
- 2021-12-10
- Primary completion
- 2025-12-10
- Completion
- 2026-12-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Surufatinib | Small molecule | 300 mg | Oral |